Today: 19 March 2026
Subscribe
Browse Category

ASX:RIO 21 January 2026 - 10 March 2026

Australia Stock Market Today: ASX 200 Rebounds After $138 Billion Rout as Oil Slide Hits Energy

Australia Stock Market Today: ASX 200 Rebounds After $138 Billion Rout as Oil Slide Hits Energy

Australian shares rebounded Tuesday, with the S&P/ASX 200 closing up 1.09% at 8,692.60 after a sharp drop the previous day. Brent crude fell about 7% as oil prices retreated from recent highs. Miners and banks led gains, while energy stocks slumped, with Woodside Energy down 3.8%. The rebound recovered only part of Monday’s A$197.1 billion market loss.
10 March 2026
····
Australia Stock Market Today: ASX 200 Suffers Worst Day in 11 Months as Oil Shock Slams Miners and Financials

Australia Stock Market Today: ASX 200 Suffers Worst Day in 11 Months as Oil Shock Slams Miners and Financials

Australia’s S&P/ASX 200 fell 2.85% to 8,599 on Monday, its worst day in 11 months, after Brent crude surged up to 25% to $119.50 a barrel amid escalating conflict in the Middle East. Materials and tech stocks led losses, while energy shares gained. Bond yields jumped to multi-year highs. G7 ministers plan to discuss emergency oil reserves as investors brace for further volatility.
9 March 2026
·····
ASX Week Ahead: CPI Day and a Flood of Big Earnings Put Australian Shares to the Test

ASX Week Ahead: CPI Day and a Flood of Big Earnings Put Australian Shares to the Test

The S&P/ASX 200 closed at 9,081.4 on Friday, just below Thursday’s record, after banks posted stronger-than-expected earnings. Rio Tinto dropped up to 4% after missing profit estimates, while QBE Insurance surged 6% on a profit beat. Key earnings from Woodside, Woolworths, Qantas, and Coles are due next week. January inflation data on Wednesday is expected to influence rate expectations.
22 February 2026
·········
ASX 200 ekes out a gain as tech snaps back; miners slide on iron ore

ASX 200 ekes out a gain as tech snaps back; miners slide on iron ore

The S&P/ASX 200 closed up 0.22% at 8,937.1, lifted by a tech rebound as WiseTech surged 12.8% and Xero rose 7.5%. Rio Tinto dropped 4.1% and Fortescue fell 4.7% as iron ore prices stayed below $100 a tonne. Investors await the Reserve Bank of Australia’s February meeting minutes and key labour data later this week.
16 February 2026
·········
Australia stock market today: ASX 200 jumps nearly 2% as tech rebounds; Pepper Money spikes on bid

Australia stock market today: ASX 200 jumps nearly 2% as tech rebounds; Pepper Money spikes on bid

The S&P/ASX 200 jumped 1.85% to 8,870.1 on Monday, erasing much of Friday’s losses as tech and real estate stocks led gains. Car Group surged 9.9% after strong results, while Pepper Money soared on a takeover bid. Australian household spending fell 0.4% in December. Traders now await major bank earnings and key U.S. economic data this week.
9 February 2026
········
Australia stock market today: ASX 200 jumps as RBA hikes rates and miners rebound

Australia stock market today: ASX 200 jumps as RBA hikes rates and miners rebound

The S&P/ASX 200 closed up 0.89% at 8,857.10 after the Reserve Bank of Australia raised its cash rate to 3.85%, the first hike in two years. Miners, tech, and banks led gains as investors adjusted to the new rate outlook. Major banks will lift variable home-loan rates by 25 basis points by mid-February. The index traded between 8,778.60 and 8,896.60 during the session.
3 February 2026
··········
Australia stock market sinks as ASX 200 hit by gold rout — what to watch before the RBA call

Australia stock market sinks as ASX 200 hit by gold rout — what to watch before the RBA call

Australian shares fell sharply Monday, with the S&P/ASX 200 down 1.02% to 8,778.6, its lowest close since January 12, as gold miners led declines. Spot gold slid 3.2% to $4,708 an ounce amid forced selling, while BHP dropped 2.3% and Santos lost 3.3%. The Aussie dollar slipped to $0.6924. Investors await Tuesday’s Reserve Bank of Australia rate decision.
2 February 2026
······
Evolution Mining Limited share price slides as gold rout deepens — what to watch next

Evolution Mining Limited share price slides as gold rout deepens — what to watch next

Evolution Mining shares fell 5.6% to A$13.88 after spot gold plunged 3.3% to $4,703 an ounce, triggering forced liquidations as CME Group raised futures margins. Northern Star Resources dropped 8%. The ASX benchmark lost 1%, with miners leading declines. Investors await the Reserve Bank of Australia’s decision Tuesday and Evolution’s half-year results next week.
2 February 2026
········
Rio Tinto stock drops as metals rout bites; Glencore clock and Brazil deal loom

Rio Tinto stock drops as metals rout bites; Glencore clock and Brazil deal loom

Rio Tinto’s U.S.-listed shares fell 4.3% to $91.03 Friday as gold, silver, and copper prices slumped, triggering a broader mining sell-off. The drop followed news of Rio and Chinalco’s $903.6 million deal to acquire control of Companhia Brasileira de Aluminio. London shares closed down 1.62%. Investors await possible updates on a Glencore tie-up by Feb. 5.
31 January 2026
·····
Australia stock market today: ASX 200 slips as miners sink, RBA rate call looms

Australia stock market today: ASX 200 slips as miners sink, RBA rate call looms

ASX 200 fell 0.65% to 8,869.1 as miners and gold stocks slumped, with Rio Tinto down 3.5% and BHP off 1.8%. Hotter-than-expected core inflation pushed markets to price in a 75% chance of an RBA rate hike next week. The Australian dollar slipped to 70.02 U.S. cents. Whitehaven reported a 21% jump in quarterly coal output to 11 million tonnes.
30 January 2026
·········
Rio Tinto share price today: stock steadies after Thursday drop as Glencore clock ticks

Rio Tinto share price today: stock steadies after Thursday drop as Glencore clock ticks

Rio Tinto shares hovered near 6,487p in early London trading Friday after a volatile week marked by strong iron ore and copper output and takeover speculation involving Glencore. Pilbara iron ore shipments rose 7% to 91.3 million tonnes in the quarter, while copper output climbed 11%. Investors await a Feb. 5 deadline for a possible Glencore bid and full-year results on Feb. 19.
23 January 2026
····
Gold breaks $4,800 as Trump tariff threat jolts markets; ASX extends selloff, Rio Tinto beats forecasts

Gold breaks $4,800 as Trump tariff threat jolts markets; ASX extends selloff, Rio Tinto beats forecasts

Gold surged past $4,800 an ounce to a new record as Australian shares fell, with the S&P/ASX 200 closing down 0.4% at 8,782. Banks dropped 1.5% to their lowest since December 1, while gold miners jumped over 13%. Wall Street rebounded after Trump announced a framework deal on Greenland and canceled planned tariffs. Rio Tinto reported record Pilbara iron ore shipments, up 7% year-on-year.
22 January 2026
····
Australia stock market today: ASX 200 slips again as banks drag; Rio, gold stocks soften the blow

Australia stock market today: ASX 200 slips again as banks drag; Rio, gold stocks soften the blow

Australia’s ASX 200 fell 0.37% to 8,782.9, its third straight drop, as financial and real estate stocks slid 1.6%. Rio Tinto rose 2.6% after Pilbara shipments beat forecasts, while BHP shares dipped 2% on cost overruns and price concessions. Gold miners rallied, with Evolution Mining up 9.18% after strong output. Wall Street’s sharp fall and new US tariff threats hit risk appetite.
21 January 2026
····
1 2 3

Stock Market Today

  • Soligenix Publishes HyBryte Clinical Data Validating Safety and Efficacy
    March 19, 2026, 2:04 PM EDT. Soligenix (NASDAQ: SNGX), a biopharmaceutical firm targeting rare diseases, reported the publication of clinical trial data on HyBryte (synthetic hypericin) in the peer-reviewed journal Expert Opinion on Investigational Drugs. The summary underscores HyBryte's safety profile, non-mutagenic mechanism, and demonstrated efficacy against cutaneous T-cell lymphoma (CTCL). The data supports HyBryte's potential as a first-line treatment. Soligenix continues its ongoing FLASH2 Phase 3 trial for HyBryte, with an interim analysis slated for Q2 2026. The company focuses on rare disease therapies and vaccine programs underpinned by proprietary technology. This publication bolsters investor confidence as Soligenix advances regulatory efforts toward global commercialization of HyBryte, expanding its pipeline across inflammatory and infectious diseases.
Go toTop